[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 50 of about 50
1. Powell S, Dudek AZ: Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res; 2009 Oct;29(10):4189-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
  • BACKGROUND: High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma.
  • The purpose of this study was to evaluate the response of metastatic melanoma to treatment with HD IL-2.
  • PATIENTS AND METHODS: A retrospective analysis was performed on all adult patients with stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at the University of Minnesota.
  • HD IL-2 was given intravenously every 8 hours at 600,000 IU/kg for a maximum of 14 doses per course.
  • RESULTS: Fifteen patients with metastatic melanoma had been treated with HD IL-2.
  • There were 4 patients exhibiting some response, with 1 complete response (CR), 1 partial response (PR), 1 mixed response (MR) and 2 stable disease (SD).
  • Average time to disease progression (TTDP) was 5.67 months.
  • Two patients had complete resolution of brain lesions after HD IL-2 therapy.
  • One of these patients experienced CR and is disease free 34 months after stopping therapy.
  • The other patient experienced MR and is currently alive with disease, but without recurrence of brain lesions.
  • CONCLUSION: We propose further evaluation of HD IL-2 in patients with brain metastases because this patient population is typically considered ineligible for HD IL-2 therapy.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. L-Lactate Dehydrogenase / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846971.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


2. Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ: A two-stage retention débridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res; 2010 Aug;468(8):2029-38
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage retention débridement protocol for acute periprosthetic joint infections.
  • QUESTIONS/PURPOSES: We determined the ability of this two-stage débridement to control infection.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Arthroplasty, Replacement, Hip. Arthroplasty, Replacement, Knee. Bone Cements. Combined Modality Therapy. Drug Delivery Systems. Female. Hip Prosthesis / adverse effects. Hip Prosthesis / microbiology. Humans. Knee Prosthesis / adverse effects. Knee Prosthesis / microbiology. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1999 Oct;81(10):1434-45 [10535593.001]
  • [Cites] Clin Orthop Relat Res. 2008 Nov;466(11):2628-33 [18781372.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):23-8 [12360003.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Clin Infect Dis. 2003 Apr 1;36(7):845-9 [12652384.001]
  • [Cites] J Arthroplasty. 2003 Oct;18(7 Suppl 1):22-6 [14560406.001]
  • [Cites] J Bone Joint Surg Am. 1974 Mar;56(2):273-84 [4452686.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] J Arthroplasty. 1990 Mar;5(1):35-9 [2319246.001]
  • [Cites] J Bone Joint Surg Am. 1990 Oct;72(9):1383-90 [2229118.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):105-12 [1959256.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):113-8 [1959257.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):98-104 [1959294.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):244-52 [1563160.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):146-50 [8895631.001]
  • [Cites] J Arthroplasty. 1996 Dec;11(8):931-8 [8986571.001]
  • [Cites] J Arthroplasty. 1997 Jun;12(4):426-33 [9195319.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3):161-5 [10195839.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] Arthroscopy. 2005 Mar;21(3):303-6 [15756183.001]
  • [Cites] J Bone Joint Surg Am. 2005 Jul;87(7):1415-22 [15995106.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12(5):433-9 [16643519.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:130-5 [17438469.001]
  • [Cites] J Bone Joint Surg Am. 2008 Aug;90(8):1637-43 [18676892.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):8-15 [12360001.001]
  • (PMID = 20224958.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2895840
  •  go-up   go-down


3. Ouyang F, Lu BS, Wang B, Yang J, Li Z, Wang L, Tang G, Xing H, Xu X, Chervin RD, Zee PC, Wang X: Sleep patterns among rural Chinese twin adolescents. Sleep Med; 2009 Apr;10(4):479-89
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine sleep patterns and influencing factors (age, gender, Tanner Stage, weekday vs. weekend, and pre-sleep activity) among rural Chinese adolescents.
  • Despite absence of late night social pressure and computers, a U-shaped TST pattern was observed across age and Tanner Stage, with a nadir around age 15-16 years or Tanner IV.
  • Bedtimes became progressively later with age and Tanner Stage, while wake-up time was considerably earlier for school students or up to Tanner IV.
  • CONCLUSIONS: Age, Tanner Stage, and pre-sleep activity affected sleep patterns in this sample of rural Chinese adolescents.

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • MedlinePlus Health Information. consumer health - Rural Health Concerns.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sleep. 2005 Mar;28(3):337-42 [16173655.001]
  • [Cites] J Sleep Res. 2005 Sep;14(3):239-44 [16120098.001]
  • [Cites] Sleep Med. 2007 Sep;8(6):602-12 [17383934.001]
  • [Cites] Prev Med. 2007 Nov;45(5):358-65 [17765960.001]
  • [Cites] Lancet. 1999 Oct 23;354(9188):1435-9 [10543671.001]
  • [Cites] Child Adolesc Psychiatr Clin N Am. 1999 Oct;8(4):695-725 [10553199.001]
  • [Cites] J Sleep Res. 2001 Mar;10(1):59-67 [11285056.001]
  • [Cites] Psychiatry Res. 2002 Aug 5;111(1):75-85 [12140122.001]
  • [Cites] Pediatrics. 2003 Feb;111(2):302-7 [12563055.001]
  • [Cites] Sleep. 2003 Jun 15;26(4):449-54 [12841371.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):885 [14586425.001]
  • [Cites] Sleep. 2004 Feb 1;27(1):101-4 [14998244.001]
  • [Cites] Sleep Med Rev. 2003 Dec;7(6):491-506 [15018092.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1021:276-91 [15251897.001]
  • [Cites] Arch Dis Child. 1969 Jun;44(235):291-303 [5785179.001]
  • [Cites] Arch Dis Child. 1970 Feb;45(239):13-23 [5440182.001]
  • [Cites] Sleep. 1980;2(4):453-60 [7403744.001]
  • [Cites] Pediatrician. 1990;17(1):13-20 [2315236.001]
  • [Cites] Pediatrician. 1990;17(1):5-12 [2315238.001]
  • [Cites] Sleep. 1993 Apr;16(3):258-62 [8506460.001]
  • [Cites] Ann Hum Genet. 1993 May;57(Pt 2):159-65 [8368806.001]
  • [Cites] Sleep. 1998 Dec 15;21(8):871-81 [9871949.001]
  • [Cites] J Adolesc Health. 1999 Jan;24(1):16-20 [9890360.001]
  • [Cites] Sleep. 2004 Nov 1;27(7):1255-73 [15586779.001]
  • [Cites] Pediatrics. 2005 Jan;115(1 Suppl):204-16 [15866854.001]
  • [Cites] Pediatrics. 2005 Jan;115(1 Suppl):250-6 [15866859.001]
  • [Cites] Pediatrics. 2005 Jun;115(6):1555-61 [15930216.001]
  • [Cites] J Appl Physiol (1985). 2005 Nov;99(5):2008-19 [16227462.001]
  • (PMID = 18752997.001).
  • [ISSN] 1389-9457
  • [Journal-full-title] Sleep medicine
  • [ISO-abbreviation] Sleep Med.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL0864619; United States / NICHD NIH HHS / HD / HD049059-01; United States / NHLBI NIH HHS / HL / 5T32HL007909-08; United States / NHLBI NIH HHS / HL / HL086461-01; United States / NHLBI NIH HHS / HL / R01 HL086461-01; United States / NICHD NIH HHS / HD / R01 HD049059-01; United States / NHLBI NIH HHS / HL / T32 HL007909; United States / NIA NIH HHS / AG / R01 AG032227; United States / NHLBI NIH HHS / HL / R01 HL086461; United States / NICHD NIH HHS / HD / R01 HD049059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Twin Study
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS129003; NLM/ PMC2753967
  •  go-up   go-down


Advertisement
4. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME: Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol; 2005 Jun;97(3):755-63
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.
  • RESULTS: Of 180 evaluable patients entered on the study with surgically staged III and IV endometrial carcinoma maximally debulked to less than 2 cm, 77 had typical endometrial adenocarcinoma and 103 had high-risk histology, either papillary serous or clear cell carcinoma.
  • Both histologic groups had similar distribution for performance status, para-aortic node positivity, site and extent of disease, and International Federation of Gynecology and Obstetrics (FIGO) stage.
  • No patient with gross residual disease survived.
  • CONCLUSION: Whole abdominal irradiation in maximally resected advanced endometrial carcinoma has tolerable toxicity, and it is suggested that the outcome may be improved by this adjunctive treatment in patients with completely resected disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Postoperative Care. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913742.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Handa VL, Cundiff G, Chang HH, Helzlsouer KJ: Female sexual function and pelvic floor disorders. Obstet Gynecol; 2008 May;111(5):1045-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study population included 301 adult women seeking outpatient gynecologic and urogynecologic care.
  • Stage III-IV prolapse was significantly associated with infrequent orgasm (P=.02), but other sexual complaints were not more common with increasing prolapse stage.

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fertil Steril. 2002 Apr;77 Suppl 4:S42-8 [12007901.001]
  • [Cites] Obstet Gynecol. 2002 Feb;99(2):281-9 [11814510.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):751-6 [15467535.001]
  • [Cites] Obstet Gynecol. 1995 Apr;85(4):483-7 [7898820.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1323-33 [9447413.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):103-13 [16021067.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jan;17(1):14-7 [15971004.001]
  • [Cites] J Sex Med. 2004 Jul;1(1):40-8 [16422982.001]
  • [Cites] Am J Obstet Gynecol. 2006 Nov;195(5):e1-4 [17074540.001]
  • [Cites] Obstet Gynecol. 2007 Apr;109(4):831-40 [17400843.001]
  • [Cites] Climacteric. 2007 Apr;10(2):132-42 [17453861.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jul;197(1):88.e1-6 [17618771.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jul;197(1):101.e1-6 [17618777.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD004014 [17636742.001]
  • [Cites] Am J Obstet Gynecol. 2007 Dec;197(6):629.e1-6 [18060957.001]
  • [Cites] J Sex Marital Ther. 2002 Oct-Dec;28(5):389-97 [12378841.001]
  • [Cites] J Sex Marital Ther. 2001 Jul-Sep;27(4):339-51 [11441518.001]
  • [CommentIn] Obstet Gynecol. 2008 May;111(5):1037-8 [18448731.001]
  • (PMID = 18448734.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K23 HD045806; United States / NICHD NIH HHS / HD / K23 HD045806-04; United States / NICHD NIH HHS / HD / K23HD045806
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS114870; NLM/ PMC2746737
  •  go-up   go-down


6. Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD: Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res; 2010 Jun 1;161(1):83-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of surgical excision on survival of patients with stage IV breast cancer.
  • BACKGROUND: Non-palliative resection of the primary tumor in stage IV breast cancer is controversial.
  • Our aim was to determine whether surgery improves survival in stage IV patients.
  • METHODS: We reviewed records of all stage IV breast cancer patients (1990-2000) at our institution.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Female. Humans. Kaplan-Meier Estimate. Linear Models. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Retrospective Studies. Virginia / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19375721.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


7. De Diego-Balaguer R, Couette M, Dolbeau G, Dürr A, Youssov K, Bachoud-Lévi AC: Striatal degeneration impairs language learning: evidence from Huntington's disease. Brain; 2008 Nov;131(Pt 11):2870-81
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Striatal degeneration impairs language learning: evidence from Huntington's disease.
  • We studied 13 pre-symptomatic gene-carriers and 22 early stage patients of Huntington's disease (pre-HD), both characterized by a progressive degeneration of the striatum and 21 late stage patients Huntington's disease (18 stage II, two stage III and one stage IV) where cortical degeneration accompanies striatal degeneration.
  • When presented with a simplified artificial language where words and rules could be extracted, early stage Huntington's disease patients (stage I) were impaired in the learning test, demonstrating a greater impairment in rule than word learning compared to the 20 age- and education-matched controls.
  • Huntington's disease patients at later stages were impaired both on word and rule learning.
  • [MeSH-major] Corpus Striatum / pathology. Huntington Disease / psychology. Language. Learning
  • [MeSH-minor] Acoustic Stimulation / methods. Adult. Aged. Attention. Cognition Disorders / etiology. Cognition Disorders / psychology. Disease Progression. Female. Heterozygote. Humans. Language Tests. Magnetic Resonance Imaging / methods. Male. Memory, Short-Term. Middle Aged. Neuropsychological Tests. Semantics. Severity of Illness Index. Transfer (Psychology)

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychologia. 2006;44(2):275-88 [15964035.001]
  • [Cites] Behav Brain Res. 2006 Jan 30;166(2):189-96 [16153716.001]
  • [Cites] Nat Neurosci. 2006 Apr;9(4):562-8 [16501567.001]
  • [Cites] Nat Rev Neurosci. 2006 Jun;7(6):464-76 [16715055.001]
  • [Cites] Rev Neurol (Paris). 2006 Jun;162(6-7):721-8 [16840980.001]
  • [Cites] Curr Pharm Des. 2006;12(21):2701-20 [16842168.001]
  • [Cites] Neuroimage. 2006 Oct 1;32(4):1562-75 [16875847.001]
  • [Cites] J Cogn Neurosci. 2006 Sep;18(9):1555-69 [16989555.001]
  • [Cites] Neuropsychologia. 2007 Jan 28;45(2):305-20 [16978666.001]
  • [Cites] Neuroimage. 2007 Jun;36(2):431-40 [17462915.001]
  • [Cites] Psychol Sci. 2007 May;18(5):387-91 [17576276.001]
  • [Cites] Psychol Rev. 2007 Jul;114(3):632-56 [17638499.001]
  • [Cites] Neuroimage. 2007 Aug 1;37(1):8-17 [17560794.001]
  • [Cites] Am J Psychiatry. 2007 Sep;164(9):1428-34 [17728429.001]
  • [Cites] Cognition. 2007 Nov;105(2):247-99 [17083927.001]
  • [Cites] Hum Brain Mapp. 2007 Nov;28(11):1089-97 [17133392.001]
  • [Cites] PLoS One. 2007;2(11):e1175 [18000546.001]
  • [Cites] J Exp Psychol Learn Mem Cogn. 2008 Jan;34(1):80-96 [18194056.001]
  • [Cites] Neuropsychologia. 2008 Apr;46(5):1391-400 [18242648.001]
  • [Cites] Cereb Cortex. 2008 Jul;18(7):1496-505 [17947346.001]
  • [Cites] Neurology. 2000 Mar 14;54(5):1117-23 [10720284.001]
  • [Cites] Neuroscience. 2000;96(3):451-74 [10717427.001]
  • [Cites] J Psycholinguist Res. 2001 Jan;30(1):37-69 [11291183.001]
  • [Cites] Nature. 2001 Jun 21;411(6840):953-6 [11418860.001]
  • [Cites] J Psycholinguist Res. 2001 May;30(3):321-38 [11523277.001]
  • [Cites] Cognition. 2002 Feb;83(1):B13-23 [11814489.001]
  • [Cites] J Neurosci. 2002 Apr 1;22(7):2541-9 [11923419.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1815-28 [12135972.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6756-65 [12151555.001]
  • [Cites] Neuron. 2002 Jul 18;35(2):371-81 [12160754.001]
  • [Cites] Science. 2002 Oct 18;298(5593):604-7 [12202684.001]
  • [Cites] Cognition. 2003 Mar;87(2):B69-77 [12590043.001]
  • [Cites] Neurology. 2003 May 27;60(10):1615-20 [12771251.001]
  • [Cites] Cognition. 2003 Nov;90(1):91-117 [14597271.001]
  • [Cites] Neuroimage. 2003 Nov;20 Suppl 1:S8-17 [14597292.001]
  • [Cites] J Int Neuropsychol Soc. 2003 Nov;9(7):1041-52 [14738285.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):213-20 [14742591.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(1):181-9 [14750976.001]
  • [Cites] Arch Clin Neuropsychol. 2004 Mar;19(2):203-14 [15010086.001]
  • [Cites] Ann Neurol. 2004 Apr;55(4):522-9 [15048891.001]
  • [Cites] Brain Lang. 2004 Jun;89(3):524-30 [15120543.001]
  • [Cites] Int J Lang Commun Disord. 2004 Jul-Sep;39(3):401-22 [15204448.001]
  • [Cites] Neurology. 1981 Oct;31(10):1333-5 [6125919.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77 [2932539.001]
  • [Cites] Cortex. 1986 Mar;22(1):11-32 [2940074.001]
  • [Cites] Neurology. 1988 Mar;38(3):341-7 [2964565.001]
  • [Cites] J Neurophysiol. 1989 Apr;61(4):814-32 [2723722.001]
  • [Cites] Brain Lang. 1989 Nov;37(4):628-42 [2479447.001]
  • [Cites] Acta Neurol Belg. 1990;90(4):207-17 [2124031.001]
  • [Cites] Neurology. 1991 Jul;41(7):1117-23 [1829794.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12(6):1217-22 [1763757.001]
  • [Cites] Neuroscience. 1995 Sep;68(2):273-85 [7477940.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] J Commun Disord. 1996 May-Jun;29(3):183-97 [8799853.001]
  • [Cites] Science. 1996 Dec 13;274(5294):1926-8 [8943209.001]
  • [Cites] Neuropsychology. 1997 Apr;11(2):272-81 [9110333.001]
  • [Cites] Science. 1997 Jul 18;277(5324):376-80 [9219696.001]
  • [Cites] Psychol Rev. 1998 Jan;105(1):158-73 [9450375.001]
  • [Cites] J Neurosci. 1998 Mar 1;18(5):1841-7 [9465008.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 May;57(5):369-84 [9596408.001]
  • [Cites] Brain. 1998 Jul;121 ( Pt 7):1343-55 [9679785.001]
  • [Cites] Stroke. 1999 Jan;30(1):100-8 [9880396.001]
  • [Cites] Brain. 1999 Sep;122 ( Pt 9):1667-78 [10468506.001]
  • [Cites] Cereb Cortex. 2004 Dec;14(12):1302-9 [15166103.001]
  • [Cites] Trends Cogn Sci. 2005 Feb;9(2):83-9 [15668101.001]
  • [Cites] Neuroreport. 2005 Feb 8;16(2):111-5 [15671857.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):584-96 [15659423.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):873-6 [15729344.001]
  • [Cites] Neuroimage. 2005 Apr 15;25(3):958-68 [15808996.001]
  • [Cites] Brain. 2005 May;128(Pt 5):1155-67 [15788544.001]
  • [Cites] Cognition. 2005 Sep;97(2):B25-34 [16226557.001]
  • [Cites] Clin Sci (Lond). 2006 Jan;110(1):73-88 [16336206.001]
  • (PMID = 18842608.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ HALMS345589; NLM/ PMC2773249
  •  go-up   go-down


8. Chambon JP, Alarcon B, N'Guyen HD, Gaillard R, Pagniez D, Dumont A: [Results of infrainguinal revascularization in patients with end-stage renal disease]. Ann Chir; 2005 Jan;130(1):26-31
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of infrainguinal revascularization in patients with end-stage renal disease].
  • OBJECTIVES: The aim of this retrospective study was to evaluate the efficacy of bypass in patients with endstage renal disease (ESRD) and to determine predictive factors and precise bypass indications.
  • METHOD: Forty one patients with ESRD underwent 50 bypass, 6 limbs were stage II and 44 stage III or IV according to Leriche and Fontaine classification.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Inguinal Canal / blood supply. Inguinal Canal / surgery. Kidney / blood supply. Male. Middle Aged. Morbidity. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664373.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Sithinamsuwan P, Niyasom S, Nidhinandana S, Supasyndh O: Dementia and depression in end stage renal disease: comparison between hemodialysis and continuous ambulatory peritoneal dialysis. J Med Assoc Thai; 2005 Nov;88 Suppl 3:S141-7
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dementia and depression in end stage renal disease: comparison between hemodialysis and continuous ambulatory peritoneal dialysis.
  • OBJECTIVES: To determine the prevalence, risk factors of dementia and depression in end stage renal disease (ESRD) who were treated with hemodialysis (HD) compared with those who had continuous ambulatory peritoneal dialysis (CAPD).
  • MATERIAL AND METHOD: A cross-sectional study was conducted on 90 ESRD patients (60 HD and 30 CAPD groups).
  • Thai Mental State Examination, DSM IV criteria and Thai Depression Inventory were interviewed to determine dementia and depression respectively.
  • In the HD group had 8.3% prevalence of dementia and 6.7% of depression, whereas there was 3.3% of dementia and 6.7% of depression in the CAPD group.
  • There was no significance different on prevalence of dementia and depression comparison between the HD and CAPD group.
  • CONCLUSION: Prevalence of dementia and depression in the overall dialysis in ESRD was 6.7% (with 8.3%, 6.7% among the HD group and 3.3%, 6.7% among CAPD group).
  • There was no significant difference on prevalence of dementia and depression comparison between the HD and CAPD group.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858952.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


10. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D: Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol; 2006 Jun;29(3):246-51
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
  • OBJECTIVE: To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC).
  • PATIENTS AND METHODS: Thirty-eight patients received 1.75 mg/m2 of oral topotecan days 1 to 5 and 175 mg/m2 paclitaxel IV over 3 hours on day 5 (after topotecan) every 4 weeks for 6 cycles.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Analysis. Topotecan / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755177.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-35629; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol; 2006 Jun;17(6):914-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
  • BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART).
  • MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004.
  • RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness.
  • Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33).
  • CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565210.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


12. Siriwardana HD, Pathirana A: Adenocarcinoma of the stomach in a tertiary care hospital in Sri Lanka. Ceylon Med J; 2007 Jun;52(2):53-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our objective was to describe the location of the tumour, stage at presentation, resectability and survival in a cohort of patients with adenocarcinoma of the stomach, presenting to a tertiary referral centre.
  • 93% had Stage III or IV disease at presentation.
  • CONCLUSION: All our patients presented with advanced gastric cancer and the majority had unresectable disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Sri Lanka / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691560.001).
  • [ISSN] 0009-0875
  • [Journal-full-title] The Ceylon medical journal
  • [ISO-abbreviation] Ceylon Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sri Lanka
  •  go-up   go-down


13. Powell SF, Dudek AZ: Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma.
  • : e20007 Background: HD IL-2 has been shown to produce durable responses in patients with metastatic melanoma.
  • METHODS: A retrospective analysis was performed all adult patients with Stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at our institution.
  • HD IL-2 was given I.V. every eight hours as a bolus over 15 minutes at a dose of 600,000 IU/kg.
  • RESULTS: A total of 15 patients with metastatic melanoma had been treated with HD IL-2 at our institution.
  • Complete response (CR) was seen in 6.67% (N=1), partial response (PR) in 6.67% (N=1), mixed response (MR) in 6.67% (N=1), and stable disease (SD) in 13.33% (N=2).
  • Average time to disease progression (TTDP) was 5.67 months in those with a PR or SD.
  • Two patients with brain metastases had subsequently complete resolution of the brain lesions after HD IL-2 therapy.
  • One of these patients has a CR and is disease free 34 months out from therapy.
  • The other had PR and is currently alive with disease, but has no recurrence of the brain lesion after over 19 months.
  • On average patients tolerated 10.5 HD IL-2 doses with the first course and 8.8 doses with the second course.
  • HD IL-2 has typically been avoided in patients with brain metastases due to concern for neurologic complications from the capillary leak syndrome caused by treatment.
  • We propose further evaluation of this ineligibility for HD IL-2, since carefully selected patients with brain metastases may derive benefit from this treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Mydlík M, Derzsiová K: [Oxalic acid--important uremic toxin]. Vnitr Lek; 2010 Jul;56(7):695-701
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM OF THE STUDY was to summarise results which we obtained during the study ofoxalic acid in biological fluids (plasma, saliva, urine and dialysate) in patients suffering from chronic kidney diseases (CKD), stage 3-5 and after renal transplantation.
  • PATIENTS AND METHODS: In the retrospective study were investigated 28 healthy subjects, 112 CKD stage 1-4 patients, 39 haemodialysis patients and 27 CAPD patients.
  • We used the following therapeutic methods: maximal water diuresis, diet with low (2g/day) and high (15g/day) sodium chloride intake, administration intravenous furosemide (20mg) and renal replacement therapy [CAPD, haemodialysis (HD), haemofiltration (HF) and postdilution haemodiafiltration (HDF)] and renal transplantation.
  • Despite of high plasma oxalic acid in uremic patients (23.1 +/- 10 micromol/l), there was no significant difference in salivary oxalic acid between control subjects (126.5 +/- 18 micromol/l) and CKD stage 3-4 patients (133.9 +/- 23.7 micromol/I).
  • The urinary excretion of oxalic acid during maximal water diuresis in healthy subjects (n = 15) (from 37.5 +/- 17.4 to 110.2 +/- 49.3 micromol/4 hours) and after intravenous furosemide (CKD stage 3-4, n = 15) (from 34.5 +/- 5.5 to 66.7 +/- 8.1 micromol/3 hours) increased significantly, but was not affected by high intake of NaCI in diet (CKD stage 3-4, n = 12).
  • Four-hour HD, H F and HDF led to the significant decrease of plasma oxalic acid, but the most significant decrease was observed during HDF (63.3%).
  • [MeSH-minor] Adult. Ascorbic Acid / metabolism. Chronic Disease. Creatinine / metabolism. Diuresis. Female. Humans. Kidney Transplantation. Male. Middle Aged. Renal Dialysis. Sodium Chloride, Dietary / pharmacology. Uremia / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. AMMONIUM OXALATE .
  • Hazardous Substances Data Bank. POTASSIUM ACID OXALATE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. OXALIC ACID .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. FERROUS OXALATE .
  • Hazardous Substances Data Bank. CHROMIUM (II) OXALATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842915.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Sodium Chloride, Dietary; 0 / Toxins, Biological; 9E7R5L6H31 / Oxalic Acid; AYI8EX34EU / Creatinine; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


15. Warady BA, Zobrist RH, Wu J, Finan E, Ferrlecit Pediatric Study Group: Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol; 2005 Sep;20(9):1320-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric patients with end-stage renal disease undergoing hemodialysis (HD) frequently develop anemia.
  • In adult patients undergoing HD, intravenous (IV) iron administration is known to replenish iron stores more effectively than oral iron administration.
  • Nevertheless, IV iron supplementation is underutilized in pediatric patients, possibly because of unproved safety in this population.
  • This international, multicenter study investigated the safety and efficacy of two dosing regimens (1.5 mg kg(-1) and 3.0 mg kg(-1)) of sodium ferric gluconate complex (SFGC) therapy, during eight consecutive HD sessions, in iron-deficient pediatric HD patients receiving concomitant rHuEPO therapy.
  • Administration of SFGC was safe and efficacious in the pediatric HD population.
  • Given the equivalent efficacy of the two doses, an initial dosing regimen of 1.5 mg kg(-1) is recommended for pediatric HD patients.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatr Nephrol. 2005 Dec;20(12):1825
  • [Cites] Nephrol Dial Transplant. 2004 Jan;19(1):141-9 [14671049.001]
  • [Cites] Clin Nephrol. 2003 Feb;59(2):115-23 [12608554.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14 (10-11):898-902 [10975295.001]
  • [Cites] Pediatr Nephrol. 2004 Jun;19(6):662-6 [15052462.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):88-97 [10873877.001]
  • [Cites] Am J Kidney Dis. 2001 Jul;38(1):109-17 [11431190.001]
  • [Cites] Pediatr Nephrol. 1991 Nov;5(6):718-23 [1768585.001]
  • [Cites] Semin Nephrol. 1989 Mar;9(1 Suppl 2):25-31 [2669083.001]
  • [Cites] Pediatr Nephrol. 2002 Aug;17(8):656-63 [12185477.001]
  • [Cites] Lancet. 1996 Oct 12;348(9033):992-6 [8855856.001]
  • [Cites] JAMA. 1999 Jun 16;281(23):2225-30 [10376576.001]
  • [Cites] Am J Kidney Dis. 2001 May;37(5):879-83 [11325667.001]
  • [Cites] Pediatr Nephrol. 1990 Nov;4(6):618-22 [2088464.001]
  • [Cites] Am J Kidney Dis. 1999 Mar;33(3):464-70 [10070910.001]
  • [Cites] Am J Kidney Dis. 1999 Mar;33(3):471-82 [10070911.001]
  • [Cites] Pediatr Nephrol. 2004 Jun;19(6):655-61 [15064942.001]
  • [Cites] Kidney Int. 1989 Jan;35(1):134-48 [2651751.001]
  • [Cites] Kidney Int. 1997 Jul;52(1):217-22 [9211366.001]
  • [Cites] Pediatr Nephrol. 2000 Dec;15(3-4):171-5 [11149105.001]
  • [Cites] Am J Kidney Dis. 1998 Feb;31(2):263-72 [9469497.001]
  • [Cites] Clin Nephrol. 1977 Nov;8(5):481-6 [589879.001]
  • [Cites] Pediatr Nephrol. 2003 Oct;18(10):1055-62 [12883982.001]
  • [Cites] Nephrol Dial Transplant. 1995;10(5):607-14 [7566570.001]
  • [Cites] Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S182-238 [11229970.001]
  • [Cites] Pediatr Nephrol. 2004 Jan;19(1):77-81 [14634860.001]
  • [Cites] Am J Kidney Dis. 1996 Oct;28(4):529-34 [8840942.001]
  • [Cites] Pediatr Nephrol. 2001 Oct;16(10):779-83 [11605781.001]
  • [Cites] Kidney Int. 2002 May;61(5):1830-9 [11967034.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1288-95 [11961017.001]
  • [Cites] J Clin Invest. 1976 Aug;58(2):447-53 [956378.001]
  • [Cites] ASAIO J. 2002 Jul-Aug;48(4):404-6 [12141472.001]
  • [Cites] Kidney Int. 2001 Dec;60(6):2406-11 [11737617.001]
  • [Cites] Pediatr Nephrol. 2004 Mar;19(3):337-40 [14745634.001]
  • [Cites] Am J Kidney Dis. 1993 Aug;22(2 Suppl 1):3-12 [8352269.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14(10-11):908-11 [10975297.001]
  • [Cites] Clin Exp Nephrol. 2003 Mar;7(1):52-7 [14586744.001]
  • [Cites] Am J Kidney Dis. 2000 Dec;36(6 Suppl 3):S39-51 [11118157.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):266-73 [14675059.001]
  • [Cites] Pediatr Nephrol. 1999 Sep;13(7):580-2 [10460505.001]
  • (PMID = 15971073.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Hematinics; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; W108RK810P / ferric gluconate
  •  go-up   go-down


16. Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, Kerr P, Robertson A, Rosman J, Paul-Brent PA, Starfield M, Polkinghorne K, Cass A: Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrol; 2009;10:1
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
  • BACKGROUND: Haemodialysis (HD) is critically dependent on the availability of adequate access to the systemic circulation, ideally via a native arteriovenous fistula (AVF).
  • METHODS/DESIGN: The study population is adult patients with stage IV or V chronic kidney disease (CKD) currently on HD or where HD is planned to start within 6 months in whom a planned upper or lower arm AVF is to be the primary HD access.
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Clinical Protocols. Double-Blind Method. Drug Combinations. Humans. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Multicenter Studies as Topic / methods

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Dial. 2000 Jan-Feb;13(1):40-6 [10740671.001]
  • [Cites] JAMA. 2008 May 14;299(18):2164-71 [18477783.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1264-9 [10982541.001]
  • [Cites] J Ren Nutr. 2000 Oct;10(4):191-5 [11070146.001]
  • [Cites] Nephrol Dial Transplant. 2000 Nov;15(11):1865-8 [11071979.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):261-6 [11167878.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2001 Jun;64(6):291-7 [11427037.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13(1):184-90 [11752036.001]
  • [Cites] J Vasc Surg. 2002 Mar;35(3):603-10 [11877717.001]
  • [Cites] Thromb Res. 2002 Feb 15;105(4):311-6 [12031825.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):429-36 [12059988.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):620-6 [12110026.001]
  • [Cites] Kidney Int. 2002 Oct;62(4):1109-24 [12234281.001]
  • [Cites] Am J Clin Nutr. 2002 Nov;76(5):1007-15 [12399272.001]
  • [Cites] Atherosclerosis. 2003 Jan;166(1):85-93 [12482554.001]
  • [Cites] J Am Soc Nephrol. 2004 Feb;15(2):477-86 [14747396.001]
  • [Cites] BMC Clin Pharmacol. 2001;1:1 [11228592.001]
  • [Cites] Redox Rep. 2004;9(4):193-7 [15479562.001]
  • [Cites] Curr Atheroscler Rep. 2004 Nov;6(6):461-7 [15485592.001]
  • [Cites] Klin Wochenschr. 1974 Apr 1;52(7):348-9 [4600820.001]
  • [Cites] Lancet. 1986 Feb 22;1(8478):414-6 [2868341.001]
  • [Cites] J Clin Invest. 1987 Jun;79(6):1788-97 [3108321.001]
  • [Cites] Lancet. 1988 Jan 16;1(8577):119 [2891958.001]
  • [Cites] Nephron. 1990;55(4):445-7 [2202923.001]
  • [Cites] Nephrol Dial Transplant. 1994;9(8):1115-20 [7800210.001]
  • [Cites] Food Chem Toxicol. 1995 Jul;33(7):553-8 [7628790.001]
  • [Cites] Scand J Urol Nephrol. 1998 Jul;32(4):276-83 [9764456.001]
  • [Cites] J Am Soc Nephrol. 1999 Oct;10(10):2177-84 [10505695.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Dec;28(6):583-9 [15531191.001]
  • [Cites] J Am Soc Nephrol. 2005 Jan;16(1):201-9 [15563567.001]
  • [Cites] Am J Kidney Dis. 2005 Mar;45(3):473-84 [15754269.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):311-8 [15954922.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Mar;1(2):182-92 [17699207.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Mar;1(2):246-55 [17699213.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Mar;1(2):332-9 [17699225.001]
  • [Cites] Am J Clin Nutr. 2000 May;71(5):1085-94 [10799369.001]
  • (PMID = 19159453.001).
  • [ISSN] 1471-2369
  • [Journal-full-title] BMC nephrology
  • [ISO-abbreviation] BMC Nephrol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Drug Combinations; 0 / Omacor; 0 / Platelet Aggregation Inhibitors; 25167-62-8 / Docosahexaenoic Acids; AAN7QOV9EA / Eicosapentaenoic Acid; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC2637871
  •  go-up   go-down


17. Larina IV, Shen W, Kelly OG, Hadjantonakis AK, Baron MH, Dickinson ME: A membrane associated mCherry fluorescent reporter line for studying vascular remodeling and cardiac function during murine embryonic development. Anat Rec (Hoboken); 2009 Mar;292(3):333-41
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High levels of mCherry are expressed in the embryonic endothelium and endocardium, and expression is also observed in capillaries in adult animals.
  • By acquiring confocal time lapses of live embryos cultured on the microscope stage, we demonstrate that the newly generated transgenic model beautifully highlights the sprouting behaviors of endothelial cells during vascular plexus formation.

  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB-Tg(Kdr-mCherry)1Medi/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Annu Rev Physiol. 2000;62:649-71 [10845106.001]
  • [Cites] Development. 2007 Sep;134(18):3317-26 [17720695.001]
  • [Cites] Genesis. 2002 Dec;34(4):228-35 [12434332.001]
  • [Cites] Genesis. 2003 Jan;35(1):1-21 [12481294.001]
  • [Cites] Nat Rev Genet. 2003 Aug;4(8):613-25 [12897773.001]
  • [Cites] Mech Dev. 2003 Nov;120(11):1407-20 [14623446.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1561-9 [15155254.001]
  • [Cites] Methods Mol Med. 2005;105:381-94 [15492409.001]
  • [Cites] Birth Defects Res C Embryo Today. 2004 Sep;72(3):260-6 [15495184.001]
  • [Cites] Development. 1993 Jun;118(2):489-98 [8223275.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4284-92 [10361126.001]
  • [Cites] Nat Biotechnol. 2004 Dec;22(12):1567-72 [15558047.001]
  • [Cites] Genesis. 2005 Jul;42(3):162-71 [15986455.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):054001 [16292961.001]
  • [Cites] Science. 2006 May 5;312(5774):751-3 [16675702.001]
  • [Cites] Dev Dyn. 2006 Nov;235(11):2940-8 [16921497.001]
  • [Cites] Nat Neurosci. 2001 Nov;4 Suppl:1215-20 [11687832.001]
  • (PMID = 19248165.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL095586-01A1; United States / NICHD NIH HHS / HD / R01 HD052115; United States / NICHD NIH HHS / HD / R01 HD052115-01A1; United States / NICHD NIH HHS / HD / R01 HD052115-05; United States / NIDDK NIH HHS / DK / DK084391-01; United States / NICHD NIH HHS / HD / HD052115-05; United States / NHLBI NIH HHS / HL / R01 HL095586; United States / NHLBI NIH HHS / HL / R01 HL077187; United States / NCI NIH HHS / CA / P30 CA008748; United States / NIDDK NIH HHS / DK / R01 DK084391; United States / NHLBI NIH HHS / HL / R01 HL 077187; United States / NICHD NIH HHS / HD / HD052115-01A1; United States / NIDDK NIH HHS / DK / R01 DK084391-01; United States / NIBIB NIH HHS / EB / R01 EB 02209; United States / NIBIB NIH HHS / EB / R01 EB002209
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / red fluorescent protein; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ NIHMS195403; NLM/ PMC2901876
  •  go-up   go-down


18. Perry SL, O'Shea SI, Byrne S, Szczech LA, Ortel TL: A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. Thromb Haemost; 2006 Dec;96(6):750-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-molecular-weight heparins undergo renal elimination, and therefore the proper dosing in hemodialysis (HD) patients is unclear.
  • It was the objective of this study to evaluate the pharmacokinetic (PK) parameters of dalteparin in patients receiving chronic HD for end-stage renal disease.
  • We performed a multidose PK study with prophylactic doses of dalteparin in twelve HD patients.
  • Dalteparin 5,000 IU was administered subcutaneously daily for four consecutive days, with HD performed on day 2 and day 4.
  • iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).
  • From this pilot PK study, we have determined initial PK parameters for dalteparin in HD patients.
  • Future studies to evaluate the PK parameters of dalteparin in patients receiving chronic HD may have to use weight-based dosing and will need to be performed over a longer period of time.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Body Weight. Drug Administration Schedule. Drug Monitoring. Factor Xa Inhibitors. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139369.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K12 RR17630-03; United States / NIDDK NIH HHS / DK / K23 DK02724-01A1; United States / NCRR NIH HHS / RR / M01-RR-30; United States / NCBDD CDC HHS / DD / U18DD00014; United States / NHLBI NIH HHS / HL / U54-HL077878
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Factor Xa Inhibitors; S79O08V79F / Dalteparin
  •  go-up   go-down


19. Prakash M, Upadhya S, Prabhu R: Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. Clin Chim Acta; 2005 Oct;360(1-2):194-8
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-transferrin bound iron (NTBI) has been found to be raised in end stage renal disease (ESRD) patients on hemodialysis (HD) receiving intravenous (IV) iron.
  • METHOD: NTBI, both ferrous (Fe(+2)) and ferric (Fe(+3)) forms, serum ferritin, protein thiols and lipid hydroperoxides were estimated by spectrophotometric and electrochemiluminescence immunoassay methods in patients with chronic renal failure (CRF), patients with ESRD on HD not receiving IV iron, and in normal controls.
  • RESULTS: NTBI (Fe(+2)) in HD patients not receiving IV iron was higher than in normal controls.
  • NTBI (Fe(+3)) was significantly higher in HD patients not on IV iron therapy than in CRF and normal controls.
  • Serum ferritin was higher in HD patients compared to CRF and normal controls.
  • There was a significant increase in lipid hydroperoxides and protein thiols in HD patients and CRF patients when compared to normal controls.
  • CONCLUSION: The source of NTBI in hemodialysis is not only IV iron therapy but also the hemodialysis procedure per se.
  • [MeSH-minor] Adult. Biomarkers / blood. Case-Control Studies. Female. Hemolysis. Humans. Lipid Peroxides / blood. Male. Middle Aged. Oxidative Stress. Sulfhydryl Compounds / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979061.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Lipid Peroxides; 0 / Sulfhydryl Compounds; E1UOL152H7 / Iron
  •  go-up   go-down


20. Gebert C, Hardes J, Ahrens H, Buerger H, Winkelmann W, Gosheger G: Primary multifocal osseous Hodgkin disease: a case report and review of the literature. J Cancer Res Clin Oncol; 2005 Mar;131(3):163-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary multifocal osseous Hodgkin disease: a case report and review of the literature.
  • PURPOSE: Hodgkin disease (HD) typically involves the lymphatic system at one or more sites.
  • Rarely, Hodgkin disease presents as an osseous lesion without involvement of lymph nodes.
  • Therefore, the histologic diagnosis of osseous HD can be problematic.
  • We present a rare case of multifocal osseous HD and a review the literature with special emphasis on treatment and prognosis.
  • METHODS: Osteomyelitis and lymphoma are the main differential diagnoses and can only be excluded histologically by the presence of Sternberg Reed cells or by immunohistochemical examinations.
  • This case reports a 21-year old man with a Hodgkin lymphoma located at the proximal femur and the proximal tibia.
  • Regarding the Ann Arbor classification, the presented case should be a stage IV disease.
  • The patient is without evidence of disease 4 years after curettage, local radiation therapy, and systemic chemotherapy despite the poor prognosis considering the Ann Arbor classification.
  • CONCLUSION: Reviewing the few reported cases, osseous HD must be distinguished from systemic HD with diffuse bone marrow involvement and from osseous metastases in advanced stage of disease because it seems to have a better prognosis.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Femur / diagnostic imaging. Femur / pathology. Humans. Immunohistochemistry. Lymphoma / diagnosis. Male. Osteomyelitis / diagnosis. Radiography. Tibia / diagnostic imaging. Tibia / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1992 Oct;(283):276-80 [1395259.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):536-44 [9469338.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Ann Hematol. 1992 Aug;65(2):61-5 [1324741.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):338-42 [7053832.001]
  • [Cites] CMAJ. 1989 May 1;140(9):1059-60 [2706592.001]
  • [Cites] Br J Surg. 1969 Apr;56(4):277-81 [4952475.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6):683-95 [2251515.001]
  • [Cites] Skeletal Radiol. 1995 Jan;24(1):61-3 [7709257.001]
  • [Cites] Radiology. 1961 Jul;77:53-60 [13702399.001]
  • [Cites] Semin Oncol. 1980 Jun;7(2):174-83 [7444471.001]
  • [Cites] Cancer Treat Rev. 1986 Jun;13(2):77-111 [3527412.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1079-85 [15205202.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):476-83 [10507773.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):79-88 [8630944.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):1041-7 [9731909.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1166-78 [10091803.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2234-6 [6488141.001]
  • [Cites] Radiol Clin North Am. 1990 Jul;28(4):841-64 [2190273.001]
  • [Cites] J Clin Oncol. 1985 Feb;3(2):215-21 [2981984.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):1035-44 [6951632.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1509-17 [7417953.001]
  • [Cites] Rontgenpraxis. 2003;55(3):114-24 [15119314.001]
  • [Cites] Am J Hematol. 1989 Mar;30(3):115-20 [2644822.001]
  • [Cites] Br J Radiol. 1967 Dec;40(480):939-48 [4952885.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1052-5 [4016696.001]
  • [Cites] Ann Intern Med. 1985 Jan;102(1):37-41 [3966743.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:98-101 [12078913.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):232-6 [6360333.001]
  • [Cites] N Engl J Med. 1964 Mar 5;270:508-14 CONTD [14089119.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1965 Mar;93:568-72 [14259982.001]
  • [Cites] Oncology. 2001;60(2):101-9 [11244323.001]
  • [Cites] Skeletal Radiol. 1979;4(4):233-5 [531588.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):204-7 [7530802.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1972 Mar;114(3):559-63 [4110941.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1786-93 [5121683.001]
  • [Cites] Australas Radiol. 1993 Feb;37(1):63-6 [8323514.001]
  • (PMID = 15605165.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


21. Hundley AF, Yuan L, Visco AG: Skeletal muscle heavy-chain polypeptide 3 and myosin binding protein H in the pubococcygeus muscle in patients with and without pelvic organ prolapse. Am J Obstet Gynecol; 2006 May;194(5):1404-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens were obtained from 17 patients with stage III or IV pelvic organ prolapse and 23 controls with minimal to no prolapse.
  • [MeSH-minor] Adult. Aged. Body Mass Index. Case-Control Studies. Computer Systems. Female. Humans. Middle Aged. Pelvic Floor. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579921.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01-HD-38680
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / MYBPH protein, human; 0 / MYH3 polypeptide, human
  •  go-up   go-down


22. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res; 2005 Oct 1;65(19):8961-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have determined the methylation frequencies of 24 CpG islands of genes associated with DNA damage responses or with ovarian cancer in 106 stage III/IV epithelial ovarian tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CpG Islands. DNA (Cytosine-5-)-Methyltransferase / genetics. DNA Methylation. Female. Genotype. Humans. Middle Aged. Neoplasm Staging. Polymorphism, Genetic


23. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • In 8 cases (44.44%) forage associated with IES was performed as the initial treatment option and 6 of these cases were found to be in Ficat stage II (75%), 1 was found to be in stage III (12.55%) and another in stage IV (12.5%).
  • In 2 cases, the central decompression technique was used (Simple Forage); both were in Ficat stage II.
  • In the other 8 cases, a total hip arthroplasty (THA) was chosen as the initial treatment option, with 3 of these patients in Ficat stage III and 5 in Ficat stage IV.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • We considered that in Ficat stage III and IV arthroplasty (THA) was the better option.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement, Hip. Decompression, Surgical. Electric Stimulation Therapy. Female. Glucocorticoids / adverse effects. Humans. Male. Middle Aged. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


24. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


25. Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V: Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma; 2005 Dec;46(12):1715-20
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients.
  • Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13% of cases of stage I-II Hodgkin lymphoma (HD).
  • It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH).
  • The comparison of IDH vs SDH can only be made in early and intermediate stages (I-II), such a comparison is not possible for advanced stages (III-IV).
  • This study retrospectively compared two groups of 1013 patients with stage I-II SDH and 101 patients with IDH (10%).
  • These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma.
  • In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95% CI, 1.3-3.4; p = 0.003).
  • After controlling for age, sex, stage, histology, B-symptoms and involvement of 3 LNA, the adjusted hazard ratio was 1.25 (95% CI, 0.65-2.4; p = 0.51) so that IDH was no longer associated with a statistically significant treatment failure rate.
  • [MeSH-major] Hodgkin Disease / physiopathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Diaphragm. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263573.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. St Peter WL, Obrador GT, Roberts TL, Collins AJ: Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis; 2005 Oct;46(4):650-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Two new intravenous (IV) iron products, ferric gluconate and iron sucrose, recently were approved for use in the United States.
  • We report trends in IV iron use in both incident (1994 to 2001) and prevalent (1994 to 2002) Medicare US dialysis patients.
  • Recombinant human erythropoietin doses, IV iron use, and hemoglobin data were obtained from Medicare outpatient files.
  • The most recent cohorts included 241,770 prevalent hemodialysis (HD) patients in 2002 and 11,744 incident HD patients in 2001.
  • RESULTS: For incident HD patients in the first 9 months of dialysis therapy, the percentage of patients administered IV iron increased sharply between 1994 and 1997 and then increased gradually between 1997 and 2001.
  • In 2002, a total of 84.4% of HD and 19.3% of peritoneal dialysis (PD) patients were administered IV iron.
  • The absolute monthly percentage of HD patients administered IV iron dextran decreased from 49.6% in January 2000 to 3.6% in December 2002.
  • CONCLUSION: In US patients with end-stage renal disease, IV iron use has increased, although slowly, from 1997 to 2002.
  • IV iron therapy was used in a much smaller percentage of PD compared with HD patients, and racial and geographic variability was observed.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Drug Utilization / trends. Erythropoietin / therapeutic use. Female. Glucaric Acid. Humans. Incidence. Infant. Infusions, Intravenous. Male. Medicare / statistics & numerical data. Middle Aged. Outpatients. Peritoneal Dialysis / statistics & numerical data. Prevalence. Recombinant Proteins. Retrospective Studies. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183420.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / N01-DK-9-2343
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 88088-23-7 / ferric gluconate; FZ7NYF5N8L / ferric oxide, saccharated; QLZ991V4A2 / Glucaric Acid
  •  go-up   go-down


27. Hall JE, Sullivan JP, Richardson GS: Brief wake episodes modulate sleep-inhibited luteinizing hormone secretion in the early follicular phase. J Clin Endocrinol Metab; 2005 Apr;90(4):2050-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the influence of sleep, sleep stage, and time of day on the dynamics of pulsatile LH secretion in the early follicular phase (EFP) of the menstrual cycle, 11 normal women underwent simultaneous polysomnographic monitoring of sleep and measurement of LH in frequent sampling studies during a 40-h protocol that consisted of one night of normal sleep and one night of sleep deprivation followed by an afternoon nap.
  • Wakefulness was more likely to be associated with an LH pulse than were stages I/II, III/IV (slow wave), or rapid eye movement sleep (P < 0.005).
  • [MeSH-minor] Adult. Electroencephalography. Female. Humans. Time Factors. Wakefulness / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671093.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-15080; United States / NCRR NIH HHS / RR / M01 RR01066; United States / NICHD NIH HHS / HD / U54 HD29164
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


28. Kim YZ, Kim KH, Kim JS, Song YJ, Kim KU, Kim HD: Clinical analysis of patients who survived for less than 3 months after brain metastatectomy. J Korean Med Sci; 2009 Aug;24(4):641-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 25 patients, 19 (79%) were of tumor stage IV and had extra-cranial metastasis.
  • [MeSH-minor] Adult. Aged. Craniotomy. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Neurol (Paris). 1992;148(6-7):477-87 [1448668.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S24-32; discusssion S1-4 [16237284.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):146-53 [8691861.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):337-44 [8823767.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:184-92 [9032860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):53-63 [9407631.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1044-55; discussion 1055-6 [9588549.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Sep;122(3):548-53 [11547308.001]
  • [Cites] Lung Cancer. 2001 Aug-Sep;33(2-3):143-54 [11551409.001]
  • [Cites] Neurosurgery. 2003 May;52(5):1066-73; discussion 1073-4 [12699548.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326 [12762877.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2114-20 [14522368.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1705-11 [15073860.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] Ann Thorac Surg. 1986 Oct;42(4):360-4 [3767508.001]
  • [Cites] Respiration. 1987;51(3):170-8 [3037658.001]
  • [Cites] Ann Thorac Surg. 1988 Jul;46(1):24-8 [3289517.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):300-4 [1648994.001]
  • [Cites] Ann Oncol. 1999 Jul;10(7):753-9 [10470420.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S253-7 [15552807.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):31-42 [16215814.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):605-16 [7674008.001]
  • (PMID = 19654946.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2719185
  • [Keywords] NOTNLM ; Brain Metastasis / Metastatectomy / Prognosis / Surgical Candidate / Survival
  •  go-up   go-down


29. van Duijn E, Giltay EJ, Zitman FG, Roos RA, van der Mast RC: Measurement of psychopathology in Huntington's disease: the critical role of caregivers. J Nerv Ment Dis; 2010 May;198(5):329-33
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of psychopathology in Huntington's disease: the critical role of caregivers.
  • Assessment of psychopathology in Huntington's disease (HD) using formal DSM-IV criteria is complex because of comorbid somatic and cognitive disturbances and diminished disease awareness.
  • Using dimensional tests in 152 HD mutation carriers, both the total score of the Problem Behaviors Assessment (PBA) scale and the behavioral section of the Unified Huntington's Disease Rating Scale (UHDRS-b) corresponded with presence of DSM-IV diagnoses.
  • Using caregiver information, subjects who were too cognitively impaired for composite international diagnostic interview assessment showed similar high PBA and UHDRS-b scores, with both a negative predictive value of 96% and a positive predictive value of 40% and 44%, respectively, for the presence of formal psychiatric disorders, indicating that dimensional rating scales and caregiver information allow for the assessment of psychopathology in advanced-stage HD.
  • [MeSH-major] Caregivers / psychology. Huntington Disease / psychology. Mental Disorders / diagnosis. Psychiatric Status Rating Scales / statistics & numerical data
  • [MeSH-minor] Adult. Attitude to Health. Awareness. Cognition Disorders / diagnosis. Cognition Disorders / epidemiology. Diagnostic and Statistical Manual of Mental Disorders. Female. Humans. International Classification of Diseases / statistics & numerical data. Male. Middle Aged. Neuropsychological Tests. Psychometrics. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458193.001).
  • [ISSN] 1539-736X
  • [Journal-full-title] The Journal of nervous and mental disease
  • [ISO-abbreviation] J. Nerv. Ment. Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Nygaard I, Handa V, Brubaker L, Borello-France D, Wei J, Wells E, Weber AM, Pelvic Floor Disorders Network: Physical activity in women planning sacrocolpopexy. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jan;18(1):33-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activity frequencies did not generally differ by prolapse stage.
  • Prolapse stage was not associated with interference with household/yard work (p=0.28) or work outside home (p=0.89).
  • Although prolapse stage is associated with interference with recreation (p=0.02), this association is not consistently positive : stage II, 42%; stage III, 22%; and stage IV, 32%.
  • [MeSH-minor] Adult. Aged. Female. Gynecologic Surgical Procedures. Housekeeping. Humans. Middle Aged. Prolapse. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):299-305 [9988790.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):903-12 [9817107.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Can J Appl Sport Sci. 1985 Sep;10(3):141-6 [4053261.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jan;188(1):108-15 [12548203.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Control Clin Trials. 2003 Oct;24(5):629-42 [14500059.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jul;187(1):88-92 [12114893.001]
  • [Cites] Am J Obstet Gynecol. 2001 Dec;185(6):1388-95 [11744914.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jun;186(6):1160-6 [12066091.001]
  • [Cites] Obstet Gynecol. 1990 May;75(5):848-51 [2325968.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1557-66 [16611949.001]
  • (PMID = 16688397.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD41249; United States / NICHD NIH HHS / HD / U10 HD41248; United States / NICHD NIH HHS / HD / U10 HD41250; United States / NICHD NIH HHS / HD / U10 HD41261; United States / NICHD NIH HHS / HD / U10 HD41263; United States / NICHD NIH HHS / HD / U10 HD41267; United States / NICHD NIH HHS / HD / U10 HD41268; United States / NICHD NIH HHS / HD / U10 HD41269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


31. Salem HA, Eissa LA, Rabbie AM, El-Helw LM, El-Gayar AM: Evaluation of some biochemical markers as prognostic factors in malignant lymphomas. Pak J Pharm Sci; 2006 Jul;19(3):219-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage.
  • For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital.
  • Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV.
  • RESULTS: 1-Pre-treatment levels of GAGs, sp55TNF-R and sL-selectin increased significantly in both HD and NHL before treatment as compared to control.
  • Pre-treatment sp55TNF-R levels in both diseases and sL-selectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sL-selectin in NHL patients had a limited value in such prediction.
  • 2- In contrast to sp55TNF-R and sL-selectin, post-treatment GAG levels are thought to be a good sign of remission in both HD and NHL.
  • 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • CONCLUSION: Pre-treatment sp55TNF-R levels in both HD & NHL and sL-selectin (only in HD patients) could be used as prognostic factor with respect to predicting treatment outcome.
  • Serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • [MeSH-major] Biomarkers, Tumor. Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Blood Cell Count. Blood Sedimentation. Female. Glycosaminoglycans / metabolism. Humans. Kidney Function Tests. L-Lactate Dehydrogenase / metabolism. L-Selectin / metabolism. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Tumor Necrosis Factor, Type I / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935830.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycosaminoglycans; 0 / Receptors, Tumor Necrosis Factor, Type I; 126880-86-2 / L-Selectin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


32. Wessels G, Bernard Hesseling P: Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa. Transfus Apher Sci; 2005 Feb;32(1):27-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
  • Hodgkin's disease (HD) in children corresponds to a large degree to HD in adults.
  • Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.
  • For practical reasons clinicians generally classify and treat NHL in children as either B-cell or T-cell disease.
  • Over the past 22 years, the Paediatric Oncology Unit of the Tygerberg Hospital has treated HD with three different regimens.
  • For the last four years HD has been treated according to the regimen suggested by Schellong with good short term survival rates.
  • BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2).
  • The majority of patients had stage III and IV disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Blood Transfusion. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. South Africa. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737871.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  • [Number-of-references] 15
  •  go-up   go-down


33. Dilek I, Ayakta H, Demir C, Meral C, Ozturk M: CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol; 2005 Feb;27(1):51-5
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
  • The study group included 69 non-Hodgkin lymphomas (NHL), 25 Hodgkin disease (HD), 20 acute myelocytic leukemia (AML), 14 chronic lymphocytic leukemia (CLL), 12 chronic myelocytic leukemia (CML), and nine multiple myeloma (MM) patients.
  • CA 125 levels were significantly higher in NHL patients with abdominal involvement (113.6 +/- 23.4 U/ml), with B-symptoms (72.3 +/- 13.2 U/ml), higher stage of the disease (stages III and IV -75.3 +/- 14.9 U/ml), bulky disease (99.9 +/- 30.4 U/ml) and in those with serosal involvement (103.1 +/- 18.5 U/ml) (P < 0.05 for all).
  • CA 125 levels were also elevated in seven patients with HD and in a patient with CLL with pleural effusion.
  • In conclusion, for patients with NHL, high levels of CA 125 were associated with B-symptoms, advanced stage, bulky disease, abdominal, and serosal involvement.
  • Therefore, CA 125 might be used as a marker to predict prognosis and to detect advanced disease in NHL.
  • [MeSH-major] CA-125 Antigen / blood. Hematologic Neoplasms / blood. Hematologic Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Leukemia / blood. Leukemia / classification. Leukemia / diagnosis. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686508.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


34. Kupka R, Msamanga GI, Aboud S, Manji KP, Duggan C, Fawzi WW: Patterns and predictors of CD4 T-cell counts among children born to HIV-infected women in Tanzania. J Trop Pediatr; 2009 Oct;55(5):290-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decreased child counts were predicted by low child anthropometry, maternal HIV stage > or =2, and maternal mid-upper arm circumference <27 cm among HIV-infected children; and by weight-for-height <-2 z-score, maternal HIV stage > or =2, maternal erythrocyte sedimentation rate <81 mm/h and maternal haemoglobin <8.5 g/dl among HIV-uninfected children.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2000 Oct;182(4):1243-6 [10979926.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):599-606 [18043314.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:298-312 [11144332.001]
  • [Cites] Pediatr Infect Dis J. 2001 Apr;20(4):397-403 [11332664.001]
  • [Cites] AIDS Rev. 2002 Jan-Mar;4(1):13-20 [11998779.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S46-9 [12142962.001]
  • [Cites] J Trop Pediatr. 2002 Dec;48(6):340-7 [12521275.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):635-41 [12902809.001]
  • [Cites] AIDS Rev. 2003 Jul-Sep;5(3):172-7 [14598566.001]
  • [Cites] Clin Diagn Lab Immunol. 2004 Jan;11(1):29-34 [14715541.001]
  • [Cites] J Trop Pediatr. 2004 Apr;50(2):94-7 [15088798.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jun;23(6):536-43 [15194835.001]
  • [Cites] Am J Clin Nutr. 2004 Jul;80(1):193-8 [15213048.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1236-43 [15464184.001]
  • [Cites] Am J Epidemiol. 1977 Sep;106(3):184-7 [900117.001]
  • [Cites] Vital Health Stat 11. 1977 Nov;(165):i-iv, 1-74 [611680.001]
  • [Cites] Scand J Infect Dis. 1987;19(2):185-92 [2956670.001]
  • [Cites] J Acquir Immune Defic Syndr. 1989;2(1):63-9 [2783971.001]
  • [Cites] J Pediatr. 1992 Feb;120(2 Pt 1):216-22 [1735817.001]
  • [Cites] Microbiol Rev. 1993 Mar;57(1):183-289 [8464405.001]
  • [Cites] Pediatrics. 1994 Apr;93(4):624-30 [8134219.001]
  • [Cites] J Pediatr. 1997 Jan;130(1):77-85 [9003854.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1332-7 [9141512.001]
  • [Cites] Nutr Rev. 1997 Apr;55(4):91-101 [9197129.001]
  • [Cites] Trop Med Int Health. 1997 May;2(5):415-21 [9217696.001]
  • [Cites] Am J Clin Nutr. 1997 Aug;66(2):464S-477S [9250134.001]
  • [Cites] JAMA. 1998 Mar 11;279(10):756-61 [9508151.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1477-82 [9605804.001]
  • [Cites] Pediatrics. 1997 Jul;100(1):E7 [9200381.001]
  • [Cites] Control Clin Trials. 1999 Feb;20(1):75-90 [10027501.001]
  • [Cites] Am J Clin Nutr. 1999 Mar;69(3):432-9 [10075327.001]
  • [Cites] Int J Epidemiol. 2005 Feb;34(1):61-8 [15649965.001]
  • [Cites] Pediatr Infect Dis J. 2005 Jul;24(7):595-600 [15998999.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):219-25 [16186741.001]
  • [Cites] Clin Infect Dis. 2005 Dec 1;41(11):1654-61 [16267740.001]
  • [Cites] J Nutr. 2007 Oct;137(10):2317-23 [17885017.001]
  • [Cites] J Infect Dis. 2000 Nov;182(5):1385-93 [11010839.001]
  • (PMID = 19158163.001).
  • [ISSN] 1465-3664
  • [Journal-full-title] Journal of tropical pediatrics
  • [ISO-abbreviation] J. Trop. Pediatr.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K24 HD058795-01A2; United States / NICHD NIH HHS / HD / K24 HD058795; United States / NICHD NIH HHS / HD / R01 HD032257; United States / FIC NIH HHS / TW / D43 TW00004; United States / PHS HHS / / R01 32257
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2766782
  •  go-up   go-down


35. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):543-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: After surgical debulking and volume-directed irradiation of the pelvis/para-aortic lymph nodes, treatment was randomized to compare recurrence-free survival (RFS) and toxicity between two chemotherapy regimens for the treatment of women with advanced stage endometrial carcinoma.
  • Accrual closed to Stage IV patients in June, 2003.
  • The hazard of recurrence or death relative to the CD arm stratified by stage is 0.90 (95% CI is 0.69 to 1.17, p=0.21, one-tail).
  • However, in subgroup analysis, CDP was associated with a 50% reduction in the risk of recurrence or death among patients with gross residual disease (95% CI: 0.26 to 0.92).
  • Stage, residual disease, histology/grade, positive para-aortic node and cytology, pelvic metastases and age were significantly associated with RFS.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108877.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA101165-04; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-22; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS102171; NLM/ PMC4459781
  •  go-up   go-down


36. Kovács AF, Mose S, Böttcher HD, Bitter K: Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol; 2005 Jan;181(1):26-34
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: 94 patients (Table 1) with primary resectable squamous cell carcinoma of the oral cavity and oropharynx (UICC stage I 14%, II 15%, III 18%, IV 53%; Table 2) were treated with a multimodality therapy program consisting of neoadjuvant intra-arterial high-dose chemotherapy (cisplatin 150 mg/m(2) with parallel systemic sodium thiosulfate 9 g/m(2) for neutralization), followed by surgery of the primary and neck, and postoperative concurrent radiation and chemotherapy with weekly docetaxel (20-30 mg/m(2); Table 3).
  • RESULTS: At a median follow-up of 4 years, the 5-year survival rate for all 94 patients was 80%, and disease-free survival was 73% (Figures 1 and 2).
  • Among patients with advanced disease (stage III and IV), survival was 83 and 59%, respectively (Figure 4).
  • CONCLUSIONS: Concurrent radiation and chemotherapy with weekly docetaxel is a feasible postoperative treatment in a multimodality approach to oral and oropharyngeal cancer, resulting in high overall and disease-free survival.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Head / pathology. Humans. Infusions, Intravenous. Injections, Intra-Arterial. Male. Middle Aged. Neck / pathology. Neck Dissection. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Care. Radiotherapy Dosage. Survival Analysis. Thiosulfates / administration & dosage. Thiosulfates / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660190.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Soleymanian T, Raman S, Shannaq FN, Richardson R, Jassal SV, Bargman J, Oreopoulos DG: Survival and morbidity of HIV patients on hemodialysis and peritoneal dialysis: one center's experience and review of the literature. Int Urol Nephrol; 2006;38(2):331-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Total follow-up of HIV-infected PD and HD patients was 248.3 and 207 patient months, respectively.
  • There was no significant difference in hospitalization rate between HIV-infected PD and HD patients (1.01 and 1.39 admission/year, respectively, P = NS).
  • Survival of HIV-infected patients on PD at one, two and three years was 100, 83, and 50%, and for HD patients was 75, 33, and 33%, respectively.
  • HIV-infected patients on HD had more prevalent advanced HIV disease.
  • Two out of seven PD patients were on PD for more than five years and one of the HD patients was on that form of dialysis for more than nine years.
  • Median survival of patients with advanced (Stage IV) AIDS (both HD and PD) was 15.1 months (range 1.6-17.3) while this value for non-advanced (Stage II, III) patients was 61.2 months (range 6.8-116.6).
  • Survival is worse in patients with advanced HIV disease.
  • [MeSH-minor] Adult. Comorbidity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Middle Aged. Peritoneal Dialysis / adverse effects. Peritoneal Dialysis / mortality. Retrospective Studies. Survival Analysis


38. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis; 2010 Jan;69(1):61-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis.
  • RESULTS: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up.
  • [MeSH-minor] Adolescent. Adult. Azathioprine / therapeutic use. Dose-Response Relationship, Drug. Drug Therapy, Combination. Epidemiologic Methods. Female. Humans. Injections, Intravenous. Kidney Function Tests. Male. Middle Aged. Proteinuria / drug therapy. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155235.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; MRK240IY2L / Azathioprine
  •  go-up   go-down


39. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


40. Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS: Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab; 2008 May;93(5):1662-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We performed a case control study of PCOS children (n = 32) compared with children from control women (n = 38) for reproductive and metabolic abnormalities, stratifying results by three Tanner stage groupings.
  • RESULTS: Urine LH levels were significantly lower in the Tanner IV-V PCOS girls compared with controls (P = 0.04).
  • We validated the correlation between salivary and serum levels of insulin (insulin areas under the curve) in an adult population [n =30, Pearson correlation coefficient (r) = 0.67; P < 0.0001], which also replicated in the children (2-h insulin r = 0.57; P = 0.0004).
  • Mean area under the curve salivary insulin levels were significantly higher in the Tanner IV-V PCOS girls in the later stages of puberty when compared with controls (3625 +/- 1372 vs. 1766 +/- 621 min x muU/ml, 95% confidence interval 475-3242; P < 0.02).

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod Update. 2006 Nov-Dec;12(6):673-83 [16891296.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Oct;91(10):4112-7 [16868051.001]
  • [Cites] N Engl J Med. 2007 Feb 8;356(6):551-66 [17287476.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):787-96 [17179197.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2739-43 [17488788.001]
  • [Cites] Metabolism. 2008 Jan;57(1):84-9 [18078863.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):172-8 [7829608.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2136-41 [15644405.001]
  • [Cites] Hum Reprod. 2005 Aug;20(8):2122-6 [15802312.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4797-802 [15899949.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):492-7 [16249280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7030-5 [16632599.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1714-22 [16492701.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):430-6 [17118995.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1021-5 [10720033.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2122-5 [11000114.001]
  • [Cites] Am J Med. 2001 Dec 1;111(8):607-13 [11755503.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2128-33 [11994352.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2134-8 [11994353.001]
  • [Cites] Fertil Steril. 2002 Sep;78(3):569-76 [12215335.001]
  • [Cites] Fertil Steril. 2004 Jan;81(1):19-25 [14711538.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2622-31 [15181033.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2494-7 [15477412.001]
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Contraception. 1974 Dec;10(6):599-605 [4448070.001]
  • [Cites] J Clin Endocrinol Metab. 1975 May;40(5):783-89 [1173241.001]
  • [Cites] J Clin Invest. 1976 May;57(5):1320-9 [770505.001]
  • [Cites] Clin Chem. 1981 Nov;27(11):1892-5 [6794948.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Lancet. 1985 Dec 21-28;2(8469-70):1375-9 [2867389.001]
  • [Cites] Diabetologia. 1986 Oct;29(10):695-8 [3542670.001]
  • [Cites] Public Health Rep. 1988 Mar-Apr;103(2):143-7 [3128829.001]
  • [Cites] Diabetes Care. 1988 Jun;11(6):489-94 [3042316.001]
  • [Cites] Am J Clin Nutr. 1991 Dec;54(6):1005-10 [1957814.001]
  • [Cites] Ultrasound Med Biol. 1991;17(6):589-93 [1962361.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1353-6 [8636332.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):942-7 [8772555.001]
  • [Cites] Pediatrics. 1996 Oct;98(4 Pt 1):649-58 [8885941.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1131-5 [9343501.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14956-60 [9843997.001]
  • [Cites] Ann Epidemiol. 2006 Jun;16(6):429-31 [16280248.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):3105-9 [16720659.001]
  • [CommentIn] J Clin Endocrinol Metab. 2008 May;93(5):1576-8 [18463351.001]
  • (PMID = 18270257.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR 016499; United States / NCRR NIH HHS / RR / M01 RR010732; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NICHD NIH HHS / HD / U54 HD 034449; United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / U54 HD034449; United States / NICHD NIH HHS / HD / K24 HD 01476; United States / NCRR NIH HHS / RR / M01 RR 10732
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadotropins; 0 / Insulin; 0 / Lipids
  • [Other-IDs] NLM/ PMC2386683
  •  go-up   go-down


41. Matos JM, Grützmann R, Agaram NP, Saeger HD, Kumar HR, Lillemoe KD, Schmidt CM: Solid pseudopapillary neoplasms of the pancreas: a multi-institutional study of 21 patients. J Surg Res; 2009 Nov;157(1):e137-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AJCC stages were stage I (18), stage II (1), stage III (2), and stage IV (0).
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Surg Res. 2010 Nov;164(1):74
  • (PMID = 19818965.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


42. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol; 2006 Sep 1;24(25):4116-22
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
  • PURPOSE: To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD).
  • PATIENTS AND METHODS: We developed a decision-analytic model to evaluate follow-up strategies for two hypothetical cohorts of 25-year-old patients with stage I-II or stage III-IV HD, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine-based chemotherapy with or without radiation therapy, respectively.
  • With adjustments for quality of life, we found a decrement in quality-adjusted life expectancy for early-stage patients followed with CT compared with non-CT modalities.
  • For advanced-stage patients, annual CT for 5 years is associated with a very small quality-adjusted survival gain over non-CT follow-up with an incremental cost-effectiveness ratio of 9,042,300 dollars/QALY.
  • CONCLUSION: Our analysis suggests that routine CT should not be used in the surveillance of asymptomatic patients in CR after treatment for HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decision Support Techniques. Hodgkin Disease / economics. Hodgkin Disease / radiography. Population Surveillance / methods. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Life Expectancy. Markov Chains. Neoplasm Staging. Predictive Value of Tests. Quality-Adjusted Life Years. Sensitivity and Specificity. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943528.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R25 CA57711-11
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


43. Jones CJ, Inuwa IM, Nardo LG, Litta P, Fazleabas AT: Eutopic endometrium from women with endometriosis shows altered ultrastructure and glycosylation compared to that from healthy controls--a pilot observational study. Reprod Sci; 2009 Jun;16(6):559-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrastructural analysis of glandular endometrial tissue from women with stages I to III endometriosis showed heterogeneous responses to the disease, biopsies often showing a mixture of features, combining delays in the maturation sequence with characteristics of later phenotypes particularly in the mid-late secretory phase of the menstrual cycle.
  • Biopsies from women with stage IV endometriosis showed immature gland morphology later in the cycle and also failed to express Dolichos biflorus agglutinin-binding glycans, suggesting an association between histological and biochemical function in advanced disease states.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282503.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / U54 HD040093; United States / NICHD NIH HHS / HD / U54HD 40093
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


44. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


45. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA, AGO-Ovar/AIO, EBMT: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol; 2007 Sep 20;25(27):4187-93
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: One hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support.
  • HD melphalan was added to the final cycle.
  • The median age was 50 years (range, 20 to 65 years) and International Federation of Gynecology and Obstetrics stage was IIb/IIc in 4%, III in 78%, and IV in 17%.
  • RESULTS: Seventy-six percent of patients received all five cycles in the HD arm and the main toxicities were neuro-/ototoxicity, gastrointestinal toxicity, and infection and one death from hemorrhagic shock.
  • After a median follow-up of 38 months, the progression-free survival was 20.5 months in the standard arm and 29.6 months in the HD arm (hazard ratio [HR], 0.84; 95% CI, 0.56 to 1.26; P, .40).
  • Median overall survival (OS) was 62.8 months in the standard arm and 54.4 months in the HD arm (HR, 1.17; 95% CI, 0.71 to 1.94; P, .54).
  • CONCLUSION: This is the first randomized trial comparing sequential HD versus standard dose chemotherapy in first-line treatment of patients with advanced ovarian cancer.
  • We observed no statistically significant difference in progression-free survival or OS and conclude that HD chemotherapy does not appear to be superior to conventional dose chemotherapy.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Melphalan / administration & dosage. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4157-8 [17698802.001]
  • (PMID = 17698804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  •  go-up   go-down


46. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


47. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS: A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer; 2008 Oct 1;113(7):1632-40
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
  • BACKGROUND: Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy.
  • RESULTS: Thirty-eight patients with treatment-naive American Joint Committee on Cancer stage IV melanoma (8 patients with M1a disease, 6 patients with M1b disease, and 24 patients with M1c disease) were enrolled.
  • Responses were observed in patients with M1a disease and in patients with M1c disease.
  • Sixteen patients had stable disease (15 patients progressed).
  • CONCLUSIONS: The current results indicated that it is safe to administer HD IL-2 sequentially with temozolomide and that this combination has lower toxicity than previously used concurrent biochemotherapy regimens.
  • However, The ORR and the durability of responses with this combination did not exceed those of single-agent HD IL-2.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer. 2013 Feb 15;119(4):924
  • (PMID = 18720480.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


48. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (&gt; or =5-year) follow-up. Am J Surg Pathol; 2005 Jun;29(6):707-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histology of the ovarian primary, extraovarian implants, and recurrent tumor(s) were characterized using World Health Organization criteria and correlated with FIGO stage and clinical follow-up.
  • After censoring nontumor deaths, overall survival and disease-free survival for the 276 patients was 95% (98% FIGO stage I; 91% FIGO II-IV) and 78% (87% FIGO stage I; 65% FIGO stage II-IV), respectively.
  • Unresectable disease (P < 0.001) and invasive implants (P < 0.001) were associated with decreased survival.
  • Stromal microinvasion in the primary tumor was also correlated with adverse outcome, independent of stage of disease, micropapillary architecture, and implant type (P = 0.03).
  • Transformation to low-grade serous carcinoma occurred in 6.8% of patients at intervals of 7 to 288 months (58% > or = 60 months) and was strongly associated with increased tempo of disease and decreased survival (P < 0.001).
  • The majority of S-LMP are clinically benign, but recurrences are not uncommon, and persistent disease as well as deaths occur.
  • Progression to low-grade serous carcinoma is highly predictive of more aggressive disease.
  • Other features associated with recurrent and/or progressive disease include FIGO stage, invasive implants, microinvasion in the primary tumor, and micropapillary architecture.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Child. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897738.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S: Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs; 2006;9(4):226-33
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 11 diabetic patients (DM) who were not receiving hemodialysis (HD), there were no amputees regardless of their Fontaine classification.
  • Of 19 patients in the HD(+)DM(-) category, there were no amputations in Fontaine stage I, II, and III patients, whereas three limbs and one toe were amputated in Fontaine stage IV patients.
  • Of 13 patients in the HD(-)DM(+) category, none of the Fontaine stage I, II, or III patients underwent amputation, but six Fontaine stage IV patients underwent amputation.
  • Of 49 patients in the HD(+)DM(+) category, 38 (78%) were classified as Fontaine stage IV, 71% (27/38) of whom had a toe or a limb amputated.
  • Therapeutic angiogenesis is effective for critically ischemic limbs resulting from hemodialysis and diabetes until Fontaine stage III, but is of limited effectiveness for stage IV cases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diabetic Angiopathies / surgery. Diabetic Nephropathies / therapy. Female. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Plethysmography. Renal Dialysis. Thermography. Vascular Endothelial Growth Factor A / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2002 Feb;13(2):497-503 [11805180.001]
  • [Cites] Lancet. 2002 Dec 21-28;360(9350):2083; author reply 2084 [12504445.001]
  • [Cites] Lancet. 2002 Aug 10;360(9331):427-35 [12241713.001]
  • [Cites] Ther Apher Dial. 2005 Feb;9(1):59-63 [15828908.001]
  • [Cites] Ther Apher Dial. 2004 Feb;8(1):3-32 [15128016.001]
  • [Cites] Helv Chir Acta. 1954 Dec;21(5-6):499-533 [14366554.001]
  • (PMID = 17171401.001).
  • [ISSN] 1434-7229
  • [Journal-full-title] Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs
  • [ISO-abbreviation] J Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


50. Peluffo MC, Barrett SL, Stouffer RL, Hennebold JD, Zelinski MB: Cumulus-oocyte complexes from small antral follicles during the early follicular phase of menstrual cycles in rhesus monkeys yield oocytes that reinitiate meiosis and fertilize in vitro. Biol Reprod; 2010 Oct;83(4):525-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stage at which follicle-enclosed cumulus-oocyte complexes achieve developmental competence in primates is unknown.
  • Ovaries were removed from adult rhesus monkeys (n = 12) during the early follicular phase (Days 3-4) of spontaneous cycles.
  • Small antral follicles were divided into five groups according to their diameter; group I: <0.5 mm; group II: 0.5-0.99 mm; group III: 1.0-1.49 mm; group IV: 1.5-1.99 mm; and group V: 2.0-2.5 mm.
  • Moreover, the inseminated oocytes can reach the morula stage but arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 1985 Mar;32(2):413-7 [3986271.001]
  • [Cites] Hum Reprod. 1987 Aug;2(6):495-7 [3667906.001]
  • [Cites] Biol Reprod. 1988 Oct;39(3):546-52 [3196788.001]
  • [Cites] Biol Reprod. 1989 Aug;41(2):335-46 [2508776.001]
  • [Cites] Reprod Nutr Dev. 1989;29(5):523-31 [2513833.001]
  • [Cites] Mol Reprod Dev. 1990 Apr;25(4):374-83 [1691651.001]
  • [Cites] Biol Reprod. 1990 Apr;42(4):703-11 [2189504.001]
  • [Cites] Mol Reprod Dev. 1990 Jan;25(1):61-6 [2393585.001]
  • [Cites] Mol Reprod Dev. 1990 Nov;27(3):261-80 [2078341.001]
  • [Cites] Biol Reprod. 1991 Jul;45(1):89-93 [1878439.001]
  • [Cites] Biol Reprod. 1993 Feb;48(2):349-56 [8439624.001]
  • [Cites] Mol Reprod Dev. 1994 Apr;37(4):467-72 [8011332.001]
  • [Cites] Fertil Steril. 1994 Aug;62(2):353-62 [8034085.001]
  • [Cites] Biol Reprod. 1994 Nov;51(5):879-87 [7849190.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1624, 1626 [10577135.001]
  • [Cites] Fertil Steril. 1999 Nov;72(5):845-51 [10560988.001]
  • [Cites] Hum Reprod. 2000 Jan;15(1):165-70 [10611207.001]
  • [Cites] Cancer Treat Rev. 1999 Dec;25(6):323-31 [10644499.001]
  • [Cites] Hum Reprod. 2000 Nov;15(11):2411-4 [11056143.001]
  • [Cites] Biol Reprod. 2001 Jul;65(1):253-9 [11420247.001]
  • [Cites] Reproduction. 2001 May;121(5):647-53 [11427152.001]
  • [Cites] Reproduction. 2001 Oct;122(4):587-92 [11570966.001]
  • [Cites] Fertil Steril. 2001 Nov;76(5):936-42 [11704114.001]
  • [Cites] Hum Reprod. 2002 Aug;17(8):2079-84 [12151440.001]
  • [Cites] Hum Reprod. 2002 Nov;17(11):2825-31 [12407033.001]
  • [Cites] Theriogenology. 2003 Feb;59(3-4):699-707 [12517374.001]
  • [Cites] Biol Reprod. 2003 Mar;68(3):812-21 [12604630.001]
  • [Cites] Hum Reprod. 2003 Apr;18(4):826-33 [12660279.001]
  • [Cites] Biol Reprod. 1994 Nov;51(5):904-12 [7849192.001]
  • [Cites] Hum Reprod. 1995 Apr;10(4):887-95 [7650138.001]
  • [Cites] Endocr Rev. 1996 Apr;17(2):121-55 [8706629.001]
  • [Cites] Mol Reprod Dev. 1996 Jun;44(2):193-9 [9115717.001]
  • [Cites] Reprod Fertil Dev. 1996;8(5):835-41 [8876042.001]
  • [Cites] Hum Reprod. 1996 Aug;11(8):1690-7 [8921118.001]
  • [Cites] Hum Reprod. 1996 Aug;11(8):1698-702 [8921119.001]
  • [Cites] Hum Reprod. 1997 Mar;12(3):403-5 [9130725.001]
  • [Cites] Fertil Steril. 1998 Jun;69(6):996-8 [9627281.001]
  • [Cites] Biol Reprod. 1998 Dec;59(6):1445-53 [9828191.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3132-8 [9853870.001]
  • [Cites] Fertil Steril. 1999 Oct;72(4):639-42 [10521101.001]
  • [Cites] Hum Reprod. 1999 Oct;14(10):2544-55 [10527985.001]
  • [Cites] Mol Reprod Dev. 2005 Jul;71(3):358-67 [15822117.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):318-21 [15983020.001]
  • [Cites] Semin Reprod Med. 2005 Aug;23(3):234-41 [16059829.001]
  • [Cites] Anim Reprod Sci. 2007 Mar;98(1-2):56-71 [17081707.001]
  • [Cites] Tissue Eng. 2006 Oct;12(10):2739-46 [17518643.001]
  • [Cites] Biol Reprod. 2007 Jun;76(6):949-57 [17287496.001]
  • [Cites] Hum Reprod. 2007 Jul;22(7):1925-31 [17437960.001]
  • [Cites] Semin Reprod Med. 2007 Jul;25(4):287-99 [17594609.001]
  • [Cites] Hum Reprod. 2007 Aug;22(8):2232-42 [17562675.001]
  • [Cites] Reprod Sci. 2007 Dec;14(8 Suppl):6-10 [18089604.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):514-22 [18971680.001]
  • [Cites] N Engl J Med. 2009 Feb 26;360(9):902-11 [19246362.001]
  • [Cites] J Reprod Dev. 2009 Feb;55(1):1-10 [19276618.001]
  • [Cites] Am J Primatol. 2009 May;71(5):384-92 [19189308.001]
  • [Cites] Pediatr Blood Cancer. 2009 Aug;53(2):289-95 [19301373.001]
  • [Cites] Biol Reprod. 2009 Sep;81(3):587-94 [19474063.001]
  • [Cites] Hum Reprod. 2009 Oct;24(10):2531-40 [19597190.001]
  • [Cites] Reprod Biomed Online. 2009 Sep;19(3):343-51 [19778479.001]
  • [Cites] Semin Reprod Med. 2009 Nov;27(6):443-9 [19806512.001]
  • [Cites] Semin Reprod Med. 2009 Nov;27(6):450-5 [19806513.001]
  • [Cites] Fertil Steril. 2010 Mar 15;93(5):1550-5 [19423101.001]
  • [Cites] Fertil Steril. 2010 May 1;93(7):2202-9 [19249763.001]
  • [Cites] Hum Reprod. 2003 Aug;18(8):1632-6 [12871873.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5307-14 [14602766.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jun 16;2:31 [15200680.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):486-93 [15044263.001]
  • [Cites] Hum Reprod. 2004 Sep;19(9):2109-17 [15243006.001]
  • [Cites] Lancet. 2004 Oct 16-22;364(9443):1405-10 [15488215.001]
  • [Cites] Lancet. 1965 Nov 6;2(7419):926-9 [4165802.001]
  • [Cites] J Exp Zool. 1974 Oct;190(1):123-7 [4436619.001]
  • [Cites] J Reprod Fertil. 1975 Oct;45(1):83-90 [1195259.001]
  • [Cites] J Reprod Fertil. 1977 Sep;51(1):1-15 [335057.001]
  • [Cites] Biol Reprod. 1982 Nov;27(4):989-97 [7171676.001]
  • [Cites] J Clin Endocrinol Metab. 1983 May;56(5):1022-31 [6403567.001]
  • [Cites] Biol Reprod. 1983 May;28(4):983-99 [6683110.001]
  • [Cites] Recent Prog Horm Res. 1983;39:1-73 [6415767.001]
  • [Cites] Dev Biol. 1984 Apr;102(2):493-7 [6706011.001]
  • (PMID = 20519694.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / RL1 HD058294; United States / NICHD NIH HHS / HD / U54 HD55744; United States / NICHD NIH HHS / HD / T32-HD007068-3; United States / NCRR NIH HHS / RR / P51 RR000163; United States / NICHD NIH HHS / HD / R01-HD058294; United States / NICHD NIH HHS / HD / RL1HD058295; United States / NCRR NIH HHS / RR / RR00163; United States / NIBIB NIH HHS / EB / PL1 EB008542; United States / NCRR NIH HHS / RR / K01 RR000163; United States / NIDCR NIH HHS / DE / UL1 DE019587; United States / NCRR NIH HHS / RR / UL1 RR024926; United States / NICHD NIH HHS / HD / RL1 HD058295; United States / NICHD NIH HHS / HD / U54 HD18185; United States / NICHD NIH HHS / HD / U54 HD055744; United States / NIDCR NIH HHS / DE / UL1DE019587; United States / NICHD NIH HHS / HD / T32 HD007068; United States / NCRR NIH HHS / RR / 1 UL1 RR024926; United States / NICHD NIH HHS / HD / U54 HD018185; United States / NIBIB NIH HHS / EB / PL1-EB008542
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2957158
  •  go-up   go-down






Advertisement